» Articles » PMID: 19756410

Diverse Immune Mechanisms May Contribute to the Survival Benefit Seen in Cancer Patients Receiving Hyperthermia

Overview
Journal Immunol Res
Date 2009 Sep 17
PMID 19756410
Citations 27
Authors
Affiliations
Soon will be listed here.
Abstract

There is increasing documentation of significant survival benefits achieved in cancer patients treated with hyperthermia in combination with radiation and/or chemotherapy. Most evidence collected regarding the mechanisms by which hyperthermia positively influences tumor control has centered on in vitro data showing the ability of heat shock temperatures (usually above 42 degrees C) to result in radio- or chemosensitization. However, these high temperatures are difficult to achieve in vivo, and new thermometry data in patients reveal that much of the tumor and surrounding region is only heated to 40-41 degrees C or less as a result of vascular drainage from the target zone of the heated tumor. Thus, there is now a growing appreciation of a role for mild hyperthermia in the stimulation of various arms of the immune system in contributing to long term protection from tumor growth. Indeed, a review of recent literature suggests the existence of an array of thermally sensitive functions which may exist naturally to help the organism to establish a new "set point" of immune responsiveness during fever. This review summarizes recent literature identifying complex effects of temperature on immune cells and potential cellular mechanisms by which increased temperature may enhance immune surveillance.

Citing Articles

Prospects of Synergy: Local Interventions and CAR T Cell Therapy in Solid Tumors.

Holtermann A, Gislon M, Angele M, Subklewe M, von Bergwelt-Baildon M, Lauber K BioDrugs. 2024; 38(5):611-637.

PMID: 39080180 PMC: 11358237. DOI: 10.1007/s40259-024-00669-y.


Hyperthermia in Combination with Emerging Targeted and Immunotherapies as a New Approach in Cancer Treatment.

Logghe T, van Zwol E, Immordino B, Van den Cruys K, Peeters M, Giovannetti E Cancers (Basel). 2024; 16(3).

PMID: 38339258 PMC: 10854776. DOI: 10.3390/cancers16030505.


BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer: Current Treatment Landscape and Novel Emerging Molecular Targets.

Claps F, Pavan N, Ongaro L, Tierno D, Grassi G, Trombetta C Int J Mol Sci. 2023; 24(16).

PMID: 37628785 PMC: 10454200. DOI: 10.3390/ijms241612596.


The Effect of Hyperthermia and Radiotherapy Sequence on Cancer Cell Death and the Immune Phenotype of Breast Cancer Cells.

Sengedorj A, Hader M, Heger L, Frey B, Dudziak D, Fietkau R Cancers (Basel). 2022; 14(9).

PMID: 35565180 PMC: 9103710. DOI: 10.3390/cancers14092050.


Low-field thoracic magnetic stimulation increases peripheral oxygen saturation levels in coronavirus disease (COVID-19) patients: A single-blind, sham-controlled, crossover study.

Dominguez-Nicolas S, Manjarrez E Medicine (Baltimore). 2021; 100(40):e27444.

PMID: 34622862 PMC: 8500560. DOI: 10.1097/MD.0000000000027444.


References
1.
Hanson D . Fever and the immune response. The effects of physiological temperatures on primary murine splenic T-cell responses in vitro. J Immunol. 1993; 151(1):436-48. View

2.
Iliakis G, Wu W, Wang M . DNA double strand break repair inhibition as a cause of heat radiosensitization: re-evaluation considering backup pathways of NHEJ. Int J Hyperthermia. 2008; 24(1):17-29. DOI: 10.1080/02656730701784782. View

3.
Ensor J, Crawford E, Hasday J . Warming macrophages to febrile range destabilizes tumor necrosis factor-alpha mRNA without inducing heat shock. Am J Physiol. 1995; 269(5 Pt 1):C1140-6. DOI: 10.1152/ajpcell.1995.269.5.C1140. View

4.
Wang X, Ostberg J, Repasky E . Effect of fever-like whole-body hyperthermia on lymphocyte spectrin distribution, protein kinase C activity, and uropod formation. J Immunol. 1999; 162(6):3378-87. View

5.
Peng J, Hyde C, Pai S, OSullivan B, Nielsen L, Thomas R . Monocyte-derived DC primed with TLR agonists secrete IL-12p70 in a CD40-dependent manner under hyperthermic conditions. J Immunother. 2006; 29(6):606-15. DOI: 10.1097/01.cji.0000211308.82997.4e. View